论文部分内容阅读
目的探讨宫颈癌和宫颈上皮内瘤变(CIN)患者血清中HPV-16 L1抗体水平及其与HPV-16感染的关系。方法收集宫颈癌患者51例和CIN(包括CINⅠ、CINⅡ、CINⅢ)患者44例。取患者宫颈病变组织并提取组织DNA,PCR检测HPV-16 DNA。同时取患者血样,酶联免疫吸附试验(ELISA)检测血清样品中HPV-16 L1抗体。结果宫颈癌组中HPV-16DNA的阳性率为82.4%,CIN组为52.3%。宫颈癌组血清HPV-16 L1抗体阳性率为70.6%,CIN组为79.5%。宫颈癌组中HPV-16 DNA阳性而HPV-16 L1抗体阴性的比例为27.5%,显著高于CIN组的9.1%(P<0.05);宫颈癌组HPV-16 DNA阴性而HPV-16L1抗体阳性的比例为15.7%,显著低于CIN组的36.4%(P<0.05)。宫颈癌组HPV-16 DNA和患者HPV-16 L1抗体均阳性的重合率为54.9%,CIN组为43.2%。结论 CIN和宫颈癌患者HPV-16 L1抗体的产生与HPV-16 DNA的检出率相关,血清中HPV-16 L1抗体可作为宫颈癌和CIN病程的辅助诊断指标。
Objective To investigate the relationship between HPV-16 L1 antibody levels and HPV-16 infection in patients with cervical cancer and cervical intraepithelial neoplasia (CIN). Methods Totally 51 patients with cervical cancer and 44 patients with CIN (including CINⅠ, CINⅡ and CINⅢ) were collected. Take patients with cervical lesions and tissue DNA, PCR detection of HPV-16 DNA. At the same time, the blood samples of the patients were collected, and the HPV-16 L1 antibody in the serum samples was detected by enzyme linked immunosorbent assay (ELISA). Results The positive rate of HPV-16 DNA in cervical cancer group was 82.4% and in CIN group was 52.3%. The positive rate of HPV-16 L1 antibody in cervical cancer group was 70.6% and that in CIN group was 79.5%. The positive rate of HPV-16 DNA in cervical cancer group was 27.5%, which was significantly higher than that in CIN group (9.1%, P <0.05). HPV-16 DNA negative and HPV-16 L1 positive In the CIN group was 15.7%, significantly lower than 36.4% in the CIN group (P <0.05). The positive coincidence rate of HPV-16 DNA in patients with cervical cancer and HPV-16 L1 antibody was 54.9% in cervical cancer group and 43.2% in CIN group. Conclusions The production of HPV-16 L1 antibody in CIN and cervical cancer patients is correlated with the detection rate of HPV-16 DNA. Serum HPV-16 L1 antibody may serve as a diagnostic indicator of the course of cervical cancer and CIN.